Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Hyperuricemia 5Tumor Lysis Syndrome 4Lymphoma 4Leukemia 4Neoplasms 2Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cytarabine 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 75Cyclophosphamide 69Busulfan 62Mycophenolic Acid 50Cyclosporine 48Tacrolimus 47Etoposide 43Whole-Body Irradiation 41Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 18Methylprednisolone 17Flow Cytometry 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14aldesleukin 12Gemtuzumab 12Thiotepa 11Bortezomib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Congenital Abnormalities × Urate Oxidase × Clear all
NCT01564277 2018-01-09

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Terminated
24 enrolled 13 charts
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡